Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab

Marina Vivarelli, Manuela Colucci, Alice Bonanni, Martina Verzani, Jessica Serafinelli, Francesco Emma, Gianmarco Ghiggeri

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment in steroid-dependent nephrotic syndrome (SDNS). However, some patients develop adverse reactions. Case-Diagnosis/Treatment: Patient 1, a 14-year-old boy with SDNS since the age of 2, was treated with oral prednisone, cyclosporine A (CsA) and mycophenolate mofetil. A first infusion of rituximab at age 12 years was well tolerated, but this was followed by a prolonged relapse unresponsive to oral prednisone, mycophenolate mofetil and CsA. A second rituximab infusion was attempted, but treatment was interrupted due to severe dyspnea. Treatment with a humanized anti-CD20 monoclonal antibody, ofatumumab, was then attempted. The patient experienced a mild allergic reaction and maintained remission despite interruption of all treatment at >12 months of follow-up. Patient 2, a 3-year-old boy who presented at 18 months with nephrotic syndrome initially resistant to treatment with oral prednisone, was given with three intravenous boluses of methylprednisolone followed by CsA and achieved remission. Upon steroid discontinuation, the NS relapsed. Prednisone was restarted and treatment with a single dose of rituximab was never completed due to a severe allergic reaction. Ofatumumab infusion was uneventful, and he maintained remission during the follow-up period (>12 months) despite interruption of prednisone therapy. B cells reappeared at 7 months in both patients. Conclusions: Ofatumumab may be a therapeutic option in severe forms of NS with allergy to rituximab.

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalPediatric Nephrology
DOIs
Publication statusAccepted/In press - Sep 29 2016

Fingerprint

Nephrotic Syndrome
Pediatrics
Prednisone
Cyclosporine
Mycophenolic Acid
Hypersensitivity
Therapeutics
Steroids
Monoclonal Antibodies
Rituximab
ofatumumab
Methylprednisolone
Dyspnea
B-Lymphocytes
Recurrence

Keywords

  • Adverse reaction
  • Children
  • Ofatumumab
  • Rituximab
  • Steroid-dependent nephrotic syndrome
  • Steroid-resistant nephrotic syndrome

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Cite this

Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab. / Vivarelli, Marina; Colucci, Manuela; Bonanni, Alice; Verzani, Martina; Serafinelli, Jessica; Emma, Francesco; Ghiggeri, Gianmarco.

In: Pediatric Nephrology, 29.09.2016, p. 1-4.

Research output: Contribution to journalArticle

@article{c5a12cdff770463d8faf0c1bd710e65f,
title = "Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab",
abstract = "Background: Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment in steroid-dependent nephrotic syndrome (SDNS). However, some patients develop adverse reactions. Case-Diagnosis/Treatment: Patient 1, a 14-year-old boy with SDNS since the age of 2, was treated with oral prednisone, cyclosporine A (CsA) and mycophenolate mofetil. A first infusion of rituximab at age 12 years was well tolerated, but this was followed by a prolonged relapse unresponsive to oral prednisone, mycophenolate mofetil and CsA. A second rituximab infusion was attempted, but treatment was interrupted due to severe dyspnea. Treatment with a humanized anti-CD20 monoclonal antibody, ofatumumab, was then attempted. The patient experienced a mild allergic reaction and maintained remission despite interruption of all treatment at >12 months of follow-up. Patient 2, a 3-year-old boy who presented at 18 months with nephrotic syndrome initially resistant to treatment with oral prednisone, was given with three intravenous boluses of methylprednisolone followed by CsA and achieved remission. Upon steroid discontinuation, the NS relapsed. Prednisone was restarted and treatment with a single dose of rituximab was never completed due to a severe allergic reaction. Ofatumumab infusion was uneventful, and he maintained remission during the follow-up period (>12 months) despite interruption of prednisone therapy. B cells reappeared at 7 months in both patients. Conclusions: Ofatumumab may be a therapeutic option in severe forms of NS with allergy to rituximab.",
keywords = "Adverse reaction, Children, Ofatumumab, Rituximab, Steroid-dependent nephrotic syndrome, Steroid-resistant nephrotic syndrome",
author = "Marina Vivarelli and Manuela Colucci and Alice Bonanni and Martina Verzani and Jessica Serafinelli and Francesco Emma and Gianmarco Ghiggeri",
year = "2016",
month = "9",
day = "29",
doi = "10.1007/s00467-016-3498-y",
language = "English",
pages = "1--4",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab

AU - Vivarelli, Marina

AU - Colucci, Manuela

AU - Bonanni, Alice

AU - Verzani, Martina

AU - Serafinelli, Jessica

AU - Emma, Francesco

AU - Ghiggeri, Gianmarco

PY - 2016/9/29

Y1 - 2016/9/29

N2 - Background: Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment in steroid-dependent nephrotic syndrome (SDNS). However, some patients develop adverse reactions. Case-Diagnosis/Treatment: Patient 1, a 14-year-old boy with SDNS since the age of 2, was treated with oral prednisone, cyclosporine A (CsA) and mycophenolate mofetil. A first infusion of rituximab at age 12 years was well tolerated, but this was followed by a prolonged relapse unresponsive to oral prednisone, mycophenolate mofetil and CsA. A second rituximab infusion was attempted, but treatment was interrupted due to severe dyspnea. Treatment with a humanized anti-CD20 monoclonal antibody, ofatumumab, was then attempted. The patient experienced a mild allergic reaction and maintained remission despite interruption of all treatment at >12 months of follow-up. Patient 2, a 3-year-old boy who presented at 18 months with nephrotic syndrome initially resistant to treatment with oral prednisone, was given with three intravenous boluses of methylprednisolone followed by CsA and achieved remission. Upon steroid discontinuation, the NS relapsed. Prednisone was restarted and treatment with a single dose of rituximab was never completed due to a severe allergic reaction. Ofatumumab infusion was uneventful, and he maintained remission during the follow-up period (>12 months) despite interruption of prednisone therapy. B cells reappeared at 7 months in both patients. Conclusions: Ofatumumab may be a therapeutic option in severe forms of NS with allergy to rituximab.

AB - Background: Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment in steroid-dependent nephrotic syndrome (SDNS). However, some patients develop adverse reactions. Case-Diagnosis/Treatment: Patient 1, a 14-year-old boy with SDNS since the age of 2, was treated with oral prednisone, cyclosporine A (CsA) and mycophenolate mofetil. A first infusion of rituximab at age 12 years was well tolerated, but this was followed by a prolonged relapse unresponsive to oral prednisone, mycophenolate mofetil and CsA. A second rituximab infusion was attempted, but treatment was interrupted due to severe dyspnea. Treatment with a humanized anti-CD20 monoclonal antibody, ofatumumab, was then attempted. The patient experienced a mild allergic reaction and maintained remission despite interruption of all treatment at >12 months of follow-up. Patient 2, a 3-year-old boy who presented at 18 months with nephrotic syndrome initially resistant to treatment with oral prednisone, was given with three intravenous boluses of methylprednisolone followed by CsA and achieved remission. Upon steroid discontinuation, the NS relapsed. Prednisone was restarted and treatment with a single dose of rituximab was never completed due to a severe allergic reaction. Ofatumumab infusion was uneventful, and he maintained remission during the follow-up period (>12 months) despite interruption of prednisone therapy. B cells reappeared at 7 months in both patients. Conclusions: Ofatumumab may be a therapeutic option in severe forms of NS with allergy to rituximab.

KW - Adverse reaction

KW - Children

KW - Ofatumumab

KW - Rituximab

KW - Steroid-dependent nephrotic syndrome

KW - Steroid-resistant nephrotic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84989180555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989180555&partnerID=8YFLogxK

U2 - 10.1007/s00467-016-3498-y

DO - 10.1007/s00467-016-3498-y

M3 - Article

AN - SCOPUS:84989180555

SP - 1

EP - 4

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

ER -